Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

Samankaltaisia teoksia

• Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
  Tekijä: Singh, Dave, et al.
  Julkaistu: (2013)
• Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
  Tekijä: Follows, Richard MA, et al.
  Julkaistu: (2013)
• A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye
  Tekijä: Musiyenko, Alla, et al.
  Julkaistu: (2009)
• Use of Propranolol Blockade to Explore the Pharmacology of GSK961081, a Bi-Functional Bronchodilator, in Healthy Volunteers: Results from Two Randomized Trials
  Tekijä: Norris, Virginia, et al.
  Julkaistu: (2014)
• Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
  Tekijä: Ambery, Claire L., et al.
  Julkaistu: (2015)